Synthesis and application of Cu2 + activated photosensitizer
By adding thiophene structure to rhodamine derivatives and combining Cu2+, Cu2+ activated photosensitizer was developed, which solved the selectivity and accuracy of photodynamic therapy for tumor treatment, and achieved efficient reactive oxygen production in NIR-II region and fluorescence imaging enhance the diagnosis and treatment effect of photodynamic therapy.
Patent Information
- Application Number
- CN202410966284.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-18
AI Technical Summary
The existing photodynamic therapy is poor in tumor elimination due to the limitation of a single spectrum when treating tumors. The activated photosensitizers have great damage to normal tissues and lack selectivity, making it difficult to achieve precise treatment.
Cu2+ activated photosensitizer is used. This photosensitizer is activated only when a specific biomarker is present, producing reactive oxygen and in the near-infrared second zone (NIR) by adding thiophene structure to rhodamine derivatives. -Ⅱ) Emit fluorescence signal for tumor diagnosis and treatment.
It realizes efficient reactive oxygen generation and fluorescence imaging in the NIR-II region, reduces damage to normal tissues, enhances the diagnosis and treatment effect of photodynamic therapy, and provides a new strategy for integrating tumor diagnosis and treatment.
Smart Images

Figure CN118908966A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biological detection and biomedicine technology, and specifically relates to a Cu 2+ Synthesis and application of activated photosensitizers. Background Art
[0002] With the continuous improvement of the quality of life, health issues are receiving more and more attention from people. In recent years, the cancer problem has become a focal issue in medical and health care and has attracted much attention. The commonly used methods for treating cancer are radiotherapy, chemotherapy and surgical resection. However, these treatment methods have more or less defects, making the treatment results unsatisfactory. Photodynamic therapy (PDT) is a non-invasive diagnosis and treatment method. Due to its many advantages such as small surgical trauma, excellent selectivity, few side effects, ability to coordinate surgical treatment, and ability to eliminate hidden lesions, it is widely used in cancer treatment and has attracted much attention from scholars.
[0003] PDT is a new disease treatment method based on the interaction between light, photosensitizer and oxygen. Photosensitizer is one of the key elements of PDT treatment. It is a photoactive substance that can absorb light energy of a specific wavelength and convert it into chemical energy, thereby triggering a series of chemical reactions. Among them, activated photosensitizers can only produce fluorescence effects and reactive oxygen under the stimulation of specific biomarkers in tumor cells. By selectively activating photosensitizers to control the production of reactive oxygen in tumor cells, tumor cells can be directly killed and toxic side effects on normal tissues can be reduced, so that tumor cells can be detected more accurately and treated more precisely. Therefore, photosensitizers that can be specifically activated by biomarkers in tumors have received widespread attention.
[0004] The wavelength of near-infrared light is between visible light and mid-infrared light, with a wavelength of 700 to 2500 nm. Near-infrared light is subdivided into different optical windows according to its wavelength. For example, the wavelength of the first near-infrared (NIR-Ⅰ) region, which was studied earlier, is in the range of 700 to 900 nm, and the wavelength of the second near-infrared (NIR-Ⅱ) region, which has been studied more in recent years, is in the range of 900 to 1700 nm. Compared with visible light and near-infrared region 1 imaging, near-infrared region 2 imaging has many advantages, such as less adverse reactions, faster imaging speed, and low autobioluminescent background. Since light has the characteristic that the scattering intensity decreases exponentially with the increase of wavelength, near-infrared region 2 imaging has better tissue penetration and spatial resolution than visible light and near-infrared region 1 imaging. Due to the complexity of the tumor microenvironment, the auxiliary effect of single photodynamic therapy on tumor elimination and immunotherapy is usually weakened. Therefore, if the advantages of NIR-Ⅱ imaging and activated photosensitizers can be combined to develop NIR-Ⅱ activated photosensitizers, it is expected to further enhance the diagnostic and therapeutic effects of photodynamic therapy.
[0005] In addition, due to Cu 2+ It can promote the growth of endothelial cells and angiogenesis, and reducing the copper content in cells by copper chelators can inhibit cell growth and angiogenesis. In summary, if we can further utilize Cu on the basis of NIR-Ⅱ activated photosensitizers, 2+ As a biomarker in cancer cells to activate photosensitizers, it will surely have broad application prospects. Summary of the invention
[0006] In order to overcome the above-mentioned shortcomings of the prior art, the present invention uses rhodamine derivatives as raw materials to construct a Cu 2+ Activated photosensitizer, the Cu 2+ Activated photosensitizers are a type of integrated diagnosis and treatment dosage form that can provide a new strategy for the integration of diagnosis and treatment in cancer treatment and have broad development prospects.
[0007] In order to achieve the above object, the technical solution adopted by the present invention is:
[0008] In a first aspect, the present invention provides a Cu 2+ Activated photosensitizer, the Cu 2+ The structural formula of the activated photosensitizer is shown below:
[0009]
[0010] The second aspect of the present invention provides the Cu 2+ The preparation method of the activated photosensitizer comprises the following steps according to the following reaction formula:
[0011]
[0012] S1, dissolving compound 2b in acetic acid, adding 2,2':5',2"-terthiophene-5-carboxaldehyde, and then reflux at 100°C-120°C for 8-15 hours. After the reaction, cooling under reduced pressure, concentrating, and purifying by column chromatography to obtain compound 2b+3t;
[0013] S2, dissolve compound 2b+3t in dichloromethane, then add NH 2 NH 2 , BOP [Carter condensation agent, also known as benzotriazol-1-yloxy tris (dimethylamino) phosphonium hexafluorophosphate] and triethylamine, then react at 35-50 ° C for 8-15 hours, after the reaction, cool under reduced pressure, concentrate and purify by column chromatography to obtain the product 3t-NH 2 NH 2 ;
[0014] S3, 3t-NH 2 NH 2 Soluble in CH 2 Cl 2 / CH 3 OH mixed solution, then add 4-bromo-2-hydroxybenzaldehyde, then reflux at 30-50°C for 10-15 hours, and purify the reaction product by column chromatography to obtain Cu 2+ Activated photosensitizer.
[0015] Only produced when specific biomarkers are present 1 O 2 The activated photosensitizer can minimize the damage to normal tissues. Among them, the photosensitizer that does not contain heavy metal atoms has the advantages of low toxicity, long triplet lifetime, good photostability and low cost. When the fluorescence emission range of the photosensitizer is in the near-infrared II region (NIR-Ⅱ) (900-1700nm), it can be used for in vivo biological imaging. Compared with visible light and near-infrared I region imaging, near-infrared II region imaging has many advantages such as small adverse reactions, fast imaging speed, deep tissue penetration, high image contrast, and low autofluorescence background. The present invention synthesizes a photosensitizer that does not contain heavy metal atoms by modifying the rhodamine derivative and adding a thiophene structure to its structure. Through experimental detection of the hair type, the synthesized photosensitizer exhibited a good singlet oxygen production ability. On this basis, the photosensitizer was further modified to obtain Cu 2+ Activated photosensitizer. By monitoring the changes in the fluorescence emission spectrum of this activated photosensitizer, it was found that this activated photosensitizer has good fluorescence emission ability in the NIR-Ⅱ region. The above research results provide new ideas for the integrated diagnosis and treatment of cancer.
[0016] Preferably, in S1, the molar ratio of the compound 2b to 2,2':5',2"-terthiophene-5-carboxaldehyde is 0.8-1.0:2.0-3.0.
[0017] Preferably, the column chromatography purification in S1 uses dichloromethane:methanol=200:1-100; v / v (more preferably 11 v / v) as the elution solvent.
[0018] Preferably, in S2, the compound 2b+3t, NH 2 NH 2 The molar ratio to BOP is 0.1-0.1:0.4-0.5:0.2-0.35.
[0019] Preferably, the column chromatography purification in S2 uses dichloromethane:methanol=500:1-100:v / v (more preferably 3v / v) as the elution solvent.
[0020] Preferably, in S3, the 3t-NH 2 NH 2 The molar ratio of 4-bromo-2-hydroxybenzaldehyde is 0.05-0.08:0.1-0.2 mmol.
[0021] Preferably, the column chromatography purification in S3 uses petroleum ether: dichloromethane = 100: 1-100: v / v (more preferably 30 v / v) as the elution solvent.
[0022] Preferably, S3 said CH 2 Cl 2 / CH 3 OH mixed solution, the CH 2 Cl 2 With CH 3 The volume ratio of OH is 1:1.
[0023] Preferably, S3 is 3t-NH 2 NH 2 In CH 2 Cl 2 / CH 3 The concentration of OH in the mixed solution is 30-50 mg / 20 mL.
[0024] The third aspect of the present invention provides the Cu 2+ Application of activated photosensitizers in the preparation of integrated tumor diagnosis and treatment preparations.
[0025] The activated photosensitizer synthesized by the method of the present invention is 2+After stimulation, a large amount of reactive oxygen and fluorescence emission can be generated through light exposure, thereby killing tumor cells. It can also produce a strong fluorescence signal in the NIR-Ⅱ region and perform NIR-Ⅱ in vivo imaging of the cancerous site. It is an integrated dosage form for tumor diagnosis and treatment with broad application prospects.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] The present invention uses rhodamine derivatives as raw materials to construct a Cu 2+ Activated photosensitizer. This NIR-Ⅱ region activated photosensitizer itself does not have the ability to emit fluorescence. 2+ After stimulation, it can be activated by light, thereby generating a large amount of reactive oxygen and fluorescence emission. The reactive oxygen generated will destroy the protein, DNA, and lipids in the cell, leading to cell apoptosis, thereby killing tumor cells; the fluorescence emission can generate a strong fluorescence signal in the NIR-Ⅱ region, and can perform NIR-Ⅱ in vivo imaging of the cancerous site. It can be seen that the Cu 2+ Activated photosensitizers are an integrated dosage form for tumor diagnosis and treatment, which can provide new ideas for the design of activated photosensitizers and have important reference significance for realizing integrated diagnosis and treatment and overcoming cancer problems. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 2b+t 1 H NMR spectrum.
[0029] Figure 2 2b+2t 1 H NMR spectra.
[0030] Figure 3 2b+3t 1 H NMR spectra.
[0031] Figure 4 2b+t 13 C NMR spectrum.
[0032] Figure 5 2b+2t 13 C NMR spectrum.
[0033] Figure 6 2b+3t 13 C NMR spectrum.
[0034] Figure 7 This is the HRMS chart of 2b+t.
[0035] Figure 8 This is the HRMS diagram of 2b+2t.
[0036] Fig. 9This is the HRMS diagram of 2b+3t.
[0037] Fig.10 10 μM photosensitizer in 10% DMSO / H 2 UV absorption spectrum in O;
[0038] Fig.11 (a) Fluorescence emission spectra of DCFH in solution at different illumination times after adding 2b+t; (b) Fluorescence emission spectra of DCFH in solution at different illumination times after adding 2b+2t; (c) Fluorescence emission spectra of DCFH in solution at different illumination times after adding 2b+3t; (d) Comparison of the fluorescence emission intensity of DCFH at 525nm over time.
[0039] Fig.12 (a) UV absorption spectra of DPBF in the solution at different illumination times after adding 2b+t; (b) UV absorption spectra of DPBF in the solution at different illumination times after adding 2b+2t; (c) UV absorption spectra of DPBF in the solution at different illumination times after adding 2b+3t; (d) comparison of the absorption intensity of DPBF at 410nm changing with illumination time.
[0040] Fig.13 Cu 2+ Activated photosensitizer 1 H NMR spectra.
[0041] Fig.14 Cu 2+ Activated photosensitizer 13 C NMR spectrum.
[0042] Fig.15 Cu 2+ HRMS spectrum of activated photosensitizer.
[0043] Fig.16 (a)Cu 2+ Activated photosensitizer plus Cu 2+ Fluorescence intensity changes of DCFH in the previous solution under different illumination times; (b) Cu 2+ Activated photosensitizer plus Cu 2+ The fluorescence intensity of DCFH in the solution changes under different illumination time; (c) After adding Cu 2+ Comparison of the fluorescence emission intensity of DCFH at 525nm in the solution before and after the change with time; the numbers in a and b are Cu 2+ Concentration (μM).
[0044] Fig.17 Cu 2+ Activated photosensitizers in different Cu 2+Fluorescence emission spectra at . DETAILED DESCRIPTION
[0045] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in each embodiment of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0046] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0047] Example 1: Synthesis and characterization of photosensitizer
[0048] 1. Synthesis of photosensitizer
[0049] The synthetic reaction formula of the photosensitizer is as follows:
[0050]
[0051] (1) Synthesis of compound 2b+t:
[0052] Compound 2b (199.9 mg, 0.42 mmol) was added to a 100 mL round-bottom flask, dissolved with 10 mL acetic acid, and then thiophene aldehyde (58 mg, 0.52 mmol) was added to the round-bottom flask, and then the resulting reaction mixture was heated at 110°C for 12 h. After the reaction was completed, the mixture was cooled and concentrated under reduced pressure, and then the obtained product was purified by column chromatography (dichloromethane: methanol = 400: 1-100; 5 v / v) to obtain the purple target product (yield 156 mg, yield 65.16%). The NMR and mass spectrometry information of the product are as follows:
[0053] 1H NMR(600MHz,Chloroform-d)δ7.96(d,J=7.7Hz,1H),7.63(td,J=7.5,1.1Hz,1H),7.57-7.52(m,2H),7.37(d,J=5.1H z,1H),7.24-7.19(m,2H),7.10(dd,J=5.1,3.6Hz,1H),6.49(d,J=8.9Hz,1H),6.44(d,J=2.5Hz,1H),6.35(dd,J=8.9 ,2.6Hz,1H),3.37(q,J=7.1Hz,4H),2.92(dddd,J=15.7,6.7,4.7,1.6Hz,1H),2.69(dddd,J=15.9,9.0,4.9,2.0Hz,1 H),2.04(ddd,J=16.0,6.3,4.7Hz,1H),1.77-1.69(m,2H),1.63(ddd,J=16.0,8.4,4.7Hz,1H),1.18(t,J=7.0Hz,6H). 13 C NMR (151 MHz, CDCl 3 )δ170.22,152.58,152.43,149.54,147.18,140.71,134.58,129.38,129.10,128.71,128.18,127.83,127.33, 126.60,125.12,123.66,118.39,108.96,108.25,105.04,97.48,44.57,27.64,23.03,22.11,12.73.ESI-MS(M) + [m / z] 470.17844, calculated as 470.17844, M = C 29 H 28 NO 3 S + .
[0054] (2) Synthesis of compound 2b+2t:
[0055] Compound 2b (463 mg, 0.97 mmol) was added to a 100 mL round-bottom flask, dissolved with 20 mL acetic acid, and then 2,2-bithiophene-5-acetaldehyde (376 mg, 1.94 mmol) was added to the round-bottom flask, and then the resulting reaction mixture was refluxed at 110°C overnight. After the reaction was completed, the mixture was cooled and concentrated under reduced pressure, and then the resulting product was purified by column chromatography (dichloromethane: methanol = 200: 1-100: 7 v / v) to obtain a blue target product (yield 318 mg, yield 50.27%). The NMR and mass spectrometry information of the product are as follows:
[0056] 1 H NMR(600MHz,Chloroform-d)δ8.01(d,J=7.7Hz,1H),7.65-7.60(m,2H),7.58-7.53(m,1H), 7.25-7.21(m,3H),7.20-7.16(m,2H),7.03(dd,J=5.1,3.6Hz,1H),6.57(d,J=8.9Hz,1H),6 .54(d,J=2.4Hz,1H),6.43(dd,J=9.1,2.5Hz,1H),3.41(q,J=7.1Hz,4H),2.91(d,J=16.3Hz ,1H),2.73(t,J=12.4Hz,1H),2.15-2.09(m,1H),1.82-1.72(m,3H),1.20(t,J=7.1Hz,6H). 13 C NMR (151 MHz, CDCl 3 )δ169.84,139.47,137.38,134.17,131.47,129.49,128.98,128.16,127.44,126.24, 125.03,124.40,124.10,124.04,97.28,44.85,27.69,23.50,21.91,12.75.ESI-MS(M) + [m / z] 552.16632, calculated as 552.16616, M = C 33 H 30 NO 3 S 2 + .
[0057] (3) Synthesis of Compound 2b+3t
[0058] Compound 2b (457 mg, 0.96 mmol) was added to a 100 mL round-bottom flask and dissolved with 20 mL of acetic acid. Then, 2,2':5',2"-terthiophene-5-carboxaldehyde (582 mg, 2.11 mmol) was added to the round-bottom flask, and the resulting reaction mixture was refluxed at 110°C overnight. After the reaction was completed, the mixture was cooled and concentrated under reduced pressure, and the resulting product was purified by column chromatography (dichloromethane: methanol = 200: 1-100; 11 v / v) to obtain a green target product (yield 387 mg, yield 54.90%). The NMR and mass spectrometry information of the product are as follows:
[0059] 1H NMR(600MHz,Chloroform-d)δ7.99(d,J=7.7Hz,1H),7.63(t,J=7.4Hz,1H),7.57-7.52(m,2H),7.24-7.22( m,1H),7.18(td,J=8.6,4.3Hz,4H),7.12(d,J=3.8Hz,1H),7.09(d,J=3.8Hz,1H),7.02(dd,J=5.1,3.6Hz,1H ),6.53(d,J=8.9Hz,1H),6.49(d,J=2.5Hz,1H),6.39(dd,J=8.9,2.6Hz,1H),3.39(q,J=7.1Hz,4H),2.91(d ,J=16.3Hz,1H),2.75-2.67(m,1H),2.08(dd,J=14.6,6.5Hz,1H),1.74-1.67(m,3H),1.19(t,J=7.1Hz,6H). 13 C NMR (151MHz, CDCl3) δ129.44,128.85,128.09,124.78,124.64,124.51,123.95,44.71,27.75,23.29,22.00,12.75.ESI-MS(M) + [m / z] 634.15388, calculated result is 634.15388, M = C 37 H 32 NO 3 S 3 + .
[0060] 2. Characterization of photosensitizers
[0061] (1) Test method
[0062] 1) Nuclear magnetic resonance test: The compound was dissolved in deuterated chloroform (CDCl) at room temperature using an AVANCE III nuclear magnetic resonance instrument produced by Bruker, Germany. 3 ) was performed, the frequency was set to 400 / 600 MHz, and the structure of the compound was determined.
[0063] 2) Mass spectrometry: A Q Exactive HF-X liquid chromatography-mass spectrometer produced by Thermo Fisher Scientific was used to determine the molecular weight of the target product.
[0064] 3) Fluorescence emission spectrum test: The FLS980 steady-state fluorescence spectrometer produced in Edinburgh, UK, was used to measure the fluorescence emission intensity of the target product under different experimental conditions, draw fluorescence emission spectra under different conditions, and analyze these spectra to obtain the fluorescence characteristics of each compound. Among them, the sensitivity is the water Raman peak signal-to-noise ratio> 12000:1, and the transient wavelength range is 300-1700nm.
[0065] 4) UV absorption spectrum test: Using the UV-2700i UV-visible spectrophotometer produced by Shimadzu Corporation of Japan, the UV absorption intensity of the target product under different experimental conditions was experimentally determined, and the UV absorption spectra under different conditions were plotted. These spectra were analyzed to obtain the generation of singlet oxygen in each compound. Quartz cuvettes (width = 1 cm) were used for all spectrophotometric and fluorescence measurements.
[0066] (2) Test results
[0067] 1) 1 H NMR, 13 C NMR and mass spectrometry characterization: The prepared compounds 2b+t, 2b+2t and 2b+3t were dissolved in deuterated chloroform and 1 H NMR ( Figure 1-3 ), 13 C NMR ( Figure 4-6 ) and mass spectrometry ( Figure 7-9 ) proved the structures of 2b+t, 2b+2t and 2b+3t.
[0068] 2) Spectroscopic determination: By measuring the photophysical properties of the three photosensitizers in solution, we can know ( Fig.10 ), with the increase of the amount of thiophene in the compound, the absorption wavelength of the photosensitizer has red shifted. Among them, the maximum absorption wavelength of 2b+t is 575nm, the maximum absorption wavelength of 2b+2t is 610nm, and the maximum absorption wavelength of 2b+3t is 632nm.
[0069] 3) Detection of reactive oxygen species: The compound 2'-7'-dichlorodihydrofluorescein (DCFH) is used as an indicator for detecting reactive oxygen species in the solution. When reactive oxygen species are generated in the system, the non-fluorescent DCFH will be oxidized and emit obvious fluorescence at 525nm. 10μM 2b+t, 2b+2t and 2b+3t were dissolved in 5mL DMSO / PBS = 1:9 (v / v) containing 5μM DCFH. The mixture was then placed in a test tube and irradiated with 3mW·cm -2 The samples were irradiated with LED light (400-800 nm), and the fluorescence intensity changes of the samples at 525 nm were recorded using a fluorescence spectrometer.
[0070] Through Fig.11 (a)(b)(c) shows that as the illumination time increases, the fluorescence emission intensity of the three photosensitizers at 525nm increases and then gradually stabilizes. This phenomenon indicates that active oxygen is generated in these three photosensitizers. Fig.11 (d) Analysis shows that the amount of active oxygen produced by these three photosensitizers as the illumination time increases is as follows: 2b+2t>2b+3t>2b+t.
[0071] 4) Singlet oxygen test: The compound 1,3-diphenylisobenzofuran (DPBF) was used as an indicator to detect the amount of singlet oxygen produced in the solution. When singlet oxygen is produced in the solution, DPBF will be oxidized by the singlet oxygen, resulting in a decrease in the absorbance of the solution at 410nm. 10μM 2b+t, 2b+2t and 2b+3t were dissolved in 5mL DMSO / PBS=1:9 (v / v) containing 25μM DPBF. The mixture was then placed in a test tube and irradiated with 3mW·cm -2 The samples were irradiated with LED light (400-800 nm) and the absorption changes of the samples at 410 nm were recorded using a UV-visible spectrophotometer.
[0072] Through Fig.12 (a)(b)(c) shows that as the illumination time increases, the ultraviolet absorption intensity of the three photosensitizers at 410nm decreases and eventually stabilizes. This phenomenon indicates that the three photosensitizers produce a large amount of singlet oxygen after illumination. Fig.12 (d) Analysis shows that as the illumination time increases, the amount of singlet oxygen produced by these three photosensitizers decreases in the order of: 2b+3t>2b+t>2b+2t.
[0073] 5) Theoretical calculation: In order to explore the relationship between the photophysical properties and structure of the photosensitizer, density functional theory was used, using the B3LYP method and the 6-31G basis set to calculate the three photosensitizers. The HOMO-LUMO orbital energy levels and orbital compositions of the frontier molecular orbitals are shown in Tables 1 and 2.
[0074] According to the data of HOMO and LOMO in Table 1, the HOMO-LUMO energy gap of 2b+t in the three compounds is 2.447eV, the HOMO-LUMO energy gap of 2b+2t is 2.175eV, and the HOMO-LUMO energy gap of 2b+3t is 1.981eV. Among them, the energy gap value of 2b+t is the largest, and the energy gap value of 2b+3t is the smallest, indicating that the energy required for the electronic transition of the molecules of the 2b+t compound is higher, and the energy required for the electronic transition of the molecules of the 2b+3t compound is lower, it is easier to be excited, and the excitation wavelength is longer.
[0075] Table 1 Energy level values of HOMO-LUMO orbitals of three photosensitizers
[0076]
[0077]
[0078] Table 2 HOMO-LUMO orbitals of three photosensitizers
[0079]
[0080] Example 2: Cu 2+ Synthesis and Characterization of Activated Photosensitizers
[0081] 1. Cu 2+ Synthesis of Activated Photosensitizer
[0082] Cu 2+ The synthetic reaction formula of the activated photosensitizer is as follows:
[0083]
[0084] The specific synthesis method is as follows: Compound 2b+3t (103 mg, 0.14 mmol) was added to a 100 mL round-bottom flask, dissolved with 20 mL of dichloromethane, and then NH 2 NH 2 (13 mg, 0.41 mmol), BOP (128 mg, 0.29 mmol) and three drops of triethylamine were added, and then reacted at 40°C overnight. After the reaction was completed, the mixture was cooled and concentrated under reduced pressure, and the obtained product was purified by column chromatography (dichloromethane: methanol = 500: 1-100: 3 v / v) to obtain the target product 3t-NH 2 NH 2 .
[0085] 3t-NH 2 NH 2 (42 mg, 0.065 mmol) was added to a round-bottom flask and stirred with 20 mL of CH 2 Cl 2 / CH 3 After the OH=1:1 (v / v) solution was dissolved, the compound 4-bromo-2-hydroxybenzaldehyde (27 mg, 0.13 mmol) was added to the round-bottom flask, and then the obtained solution was refluxed at 40°C for 12 hours. After the reaction, the obtained product was purified by column chromatography (petroleum ether: dichloromethane = 100:1-100:30 v / v) to obtain the yellow-green solid target product Cu 2+Activated photosensitizer (yield 26 mg, yield 48.14%). The NMR information of the product is as follows:
[0086] 1 H NMR(600MHz,Chloroform-d)δ11.17(s,1H),9.34(s,1H),7.95(d,J=7.6Hz,1H),7.59(td,J=7.5,1.2Hz,1H),7.55-7.50(m,2H),7 .25(d,J=7.6Hz,1H),7.22(dd,J=5.1,1.1Hz,1H),7.19-7.15(m,3H),7.11(d,J=3.8Hz,1H),7.09(d,J=3.8Hz,1H),7.06(d,J=1.9H z,1H),7.04-7.01(m,2H),6.96(dd,J=8.3,1.9Hz,1H),6.49-6.46(m,1H),6.42(d,J=8.8Hz,1H),6.30-6.26(m,1H),3.34(q,J=7. 1Hz,4H),2.92-2.86(m,1H),2.75-2.68(m,1H),1.84-1.77(m,1H),1.68(dtq,J=12.6,8.5,4.8,4.0Hz,3H),1.17(t,J=7.0Hz,6H). 13 CNMR (101MHz, CDCl 3 )δ164.86,159.52,152.65,152.57,149.24,149.07,147.64,139.90,138.10,137.25 ,136.56,136.29,133.73,132.43,130.31,129.06,128.06,127.96,127.87,125.42,1 24.71,124.60,124.32,123.89,123.82,123.67,122.55,120.57,117.97,117.75,10 8.92,108.39,104.24,97.88,68.35,44.45,27.90,22.91,22.16,12.79.ESI-MS(M+H) + [m / z] 832.11670, calculated as 832.11804, M = C 44 H 36 Bn 3 O 3 S 3 .
[0087] 2. Cu 2+Characterization of activated photosensitizers:
[0088] 1) 1 H NMR, 13 C NMR and mass spectrometry characterization: The new compound Cu was obtained by modifying the 2b+3T structure and purifying it. 2+ Activated photosensitizer. This activated photosensitizer is dissolved in deuterated chloroform and 1 H NMR ( Fig.13 ), 13 C NMR ( Fig.14 ) and mass spectrometry ( Fig.15 ) detection, proving that Cu 2+ Structure of activated photosensitizer.
[0089] 2)Cu 2+ Reactive oxygen species testing before and after the addition of activated photosensitizer markers: measuring Cu 2+ Reactive oxygen species under different illumination times (min) before and after the addition of activated photosensitizer to the marker, such as Fig.16 As shown in the figure, it can be seen that the fluorescence of the activated photosensitizer is significantly enhanced after the addition of the marker, indicating that this activated photosensitizer can be successfully activated to produce a large amount of reactive oxygen. Fig.16 (c) It can be seen that when Cu is added 2+ After that, the rising trend of the fluorescence intensity at 525 nm slowed down, which is inferred that Cu 2+ May affect the production of reactive oxygen species.
[0090] 3)Cu 2+ NIR-II region spectrum of activated photosensitizers: The fluorescence emission spectrum of activated photosensitizers in the NIR-II region is explored, such as Fig.17 As shown. Fig.17 Analysis shows that this activated photosensitizer is activated by Cu 2+ As the content of α-hydroxy-1-nitropropene increases, the fluorescence emission intensity in the NIR-Ⅱ region continues to increase. This shows that this activated photosensitizer has good fluorescence imaging potential.
[0091] In summary, the present invention synthesized three photosensitizers by modifying rhodamine derivatives and controlling the number of thiophenes connected thereto. According to the heavy atom effect, the presence of sulfur atoms in these three photosensitizers enhances spin-orbit coupling, thereby promoting intersystem crossing and generating more reactive oxygen. Experiments have found that the photosensitizer 2b+3t, which contains the most thiophenes, produces the most singlet oxygen. This work provides a new idea for constructing photosensitizers that do not contain heavy metals.
[0092] At the same time, the present invention constructs a Cu 2+Activated photosensitizers retain the characteristics of rhodamine dyes. After being specifically activated by tumor markers, they can produce a large amount of singlet oxygen through ring opening. They have the advantages of strong stability, easy synthesis, and high biocompatibility. Experiments have found that this activated photosensitizer can produce strong fluorescence emission in the NIR-Ⅱ region and can be used for NIR-Ⅱ in vivo imaging of cancerous sites. This work provides a new strategy for the integration of diagnosis and treatment of cancer treatment and has broad development prospects.
[0093] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the protection scope of the present invention.
Claims
1. A Cu 2+ Activated photosensitizer, It is characterized in that The Cu 2+ The structural formula of the activated photosensitizer is shown below:
2. Cu according to claim 1 2+ Preparation method of activated photosensitizer, It is characterized in that According to the following reaction formula, the preparation method comprises the following steps: S1, dissolving compound 2b in acetic acid, adding 2,2':5',2"-terthiophene-5-carboxaldehyde, and then reflux at 100°C-120°C for 8-15 hours. After the reaction, cooling under reduced pressure, concentrating, and purifying by column chromatography to obtain compound 2b+3t; S2, dissolve compound 2b+3t in dichloromethane, then add NH 2 NH 2 , BOP and triethylamine, then react at 35-50°C for 8-15 hours, and after the reaction, cool under reduced pressure, concentrate and purify by column chromatography to obtain the product 3t-NH 2 NH 2 ; S3, 3t-NH 2 NH 2 Soluble in CH 2 Cl 2 / CH 3 OH mixed solution, then add 4-bromo-2-hydroxybenzaldehyde, then reflux at 30-50°C for 10-15 hours, and purify the reaction product by column chromatography to obtain Cu 2+ Activated photosensitizer.
3. Cu according to claim 2 2+ Preparation method of activated photosensitizer, It is characterized in that In S2, the compound 2b+3t, NH 2 NH 2 The molar ratio to BOP is 0.1-0.1:0.4-0.5:0.2-0.
35.
4. Cu according to claim 2 2+ Preparation method of activated photosensitizer, It is characterized in that The column chromatography purification in S2 uses dichloromethane:methanol=500:1-100:v / v as the elution solvent.
5. The Cu according to claim 2 2+ Preparation method of activated photosensitizer, It is characterized in that In S3, the 3t-NH 2 NH 2 The molar ratio of 4-bromo-2-hydroxybenzaldehyde is 0.05-0.08:0.1-0.2 mmol.
6. The Cu according to claim 2 2+ Preparation method of activated photosensitizer, It is characterized in that The column chromatography purification in S3 uses petroleum ether: dichloromethane = 100: 1-100: v / v as the elution solvent.
7. The Cu according to claim 2 2+ Preparation method of activated photosensitizer, It is characterized in that S3 CH 2 Cl 2 / CH 3 OH mixed solution, the CH 2 Cl 2 With CH 3 The volume ratio of OH is 1:
1.
8. The Cu according to claim 2 2+ Preparation method of activated photosensitizer, It is characterized in that S3 3t-NH 2 NH 2 In CH 2 Cl 2 / CH 3 The concentration of OH in the mixed solution is 30-50 mg / 20 mL.
9. The Cu according to claim 1 2+ Application of activated photosensitizers in the preparation of integrated tumor diagnosis and treatment preparations.
Citation Information
Patent Citations
Rhodamine-containing lactam group micromolecule pH fluorescent probe and synthetic method
CN104017569A
Fluorescent probe for detecting acetylcholin esterase as well as preparation method and application of fluorescent probe
CN115215769A
Small molecule pyroptosis inducer and application thereof as tumor sonodynamic therapeutic agent
CN117603197A
Near-infrared fluorescent probe, preparation method thereof and application of near-infrared fluorescent probe in dual-response detection of Cu < 2 + > and A < beta > aggregate
CN117800982A
Cited By
A beta plaque specific response type near-infrared fluorescent probe as well as preparation method and application thereof
CN120965671A
Abeta plaque-specific near-infrared fluorescent probe and preparation method and application thereof
CN120965671B
